Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Protective Effects of Tumor Necrosis Factor on Murine Hematopoiesis during Cycle-specific Cytotoxic Chemotherapy

Protective Effects of Tumor Necrosis Factor on Murine Hematopoiesis during Cycle-specific... Tumor necrosis factor (TNF) is a pleiotropic cytokine which exerts a wide range of effects when administered in vivo . Using a murine model, we have investigated the effect of pretreatment with 1 µg (2.6 x 10 4 units) per mouse of recombinant murine TNF- on hematopoietic recovery following administration of cyclophosphamide, 5-fluorouracil, methotrexate, or vinblastine. TNF pretreatment results in enhanced regeneration of circulating neutrophils and hematopoietic progenitors, as measured by in vivo and in vitro assays, in animals given cycle-specific chemotherapeutic agents. The results may suggest that TNF affects cycle kinetics in hematopoietic progenitor cell populations, thus making these cells less prone to the cytocidal effects of the chemotherapeutic agents. As myeloablation is a frequent and often critical side effect following cancer treatment, these findings may have clinical implications. 1 This work was supported by USPHS Grants CA032516, CA-20194, and CA-23766 from the National Cancer Institute; American Cancer Society Grant CA-3K; and the Gar Reichman Fund of the Cancer Research Institute. D. J. W. is supported by a fellowship of the Leukemia Society of America. 2 Fellow of the Norwegian Cancer Society. To whom requests for reprints should be addressed, at the Clinical Pharmacology Unit, Department of Pharmacology and Toxicology, University of Bergen, N-5021 Bergen, Norway. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Cancer Research American Association of Cancer Research

Protective Effects of Tumor Necrosis Factor on Murine Hematopoiesis during Cycle-specific Cytotoxic Chemotherapy

Cancer Research , Volume 50 (14): 4216 – Jul 15, 1990

Protective Effects of Tumor Necrosis Factor on Murine Hematopoiesis during Cycle-specific Cytotoxic Chemotherapy

Cancer Research , Volume 50 (14): 4216 – Jul 15, 1990

Abstract

Tumor necrosis factor (TNF) is a pleiotropic cytokine which exerts a wide range of effects when administered in vivo . Using a murine model, we have investigated the effect of pretreatment with 1 µg (2.6 x 10 4 units) per mouse of recombinant murine TNF- on hematopoietic recovery following administration of cyclophosphamide, 5-fluorouracil, methotrexate, or vinblastine. TNF pretreatment results in enhanced regeneration of circulating neutrophils and hematopoietic progenitors, as measured by in vivo and in vitro assays, in animals given cycle-specific chemotherapeutic agents. The results may suggest that TNF affects cycle kinetics in hematopoietic progenitor cell populations, thus making these cells less prone to the cytocidal effects of the chemotherapeutic agents. As myeloablation is a frequent and often critical side effect following cancer treatment, these findings may have clinical implications. 1 This work was supported by USPHS Grants CA032516, CA-20194, and CA-23766 from the National Cancer Institute; American Cancer Society Grant CA-3K; and the Gar Reichman Fund of the Cancer Research Institute. D. J. W. is supported by a fellowship of the Leukemia Society of America. 2 Fellow of the Norwegian Cancer Society. To whom requests for reprints should be addressed, at the Clinical Pharmacology Unit, Department of Pharmacology and Toxicology, University of Bergen, N-5021 Bergen, Norway.

Loading next page...
 
/lp/american-association-of-cancer-research/protective-effects-of-tumor-necrosis-factor-on-murine-hematopoiesis-iSLAf3uKgG

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
American Association of Cancer Research
Copyright
Copyright © 1990 by the American Association for Cancer Research.
ISSN
0008-5472
Publisher site

Abstract

Tumor necrosis factor (TNF) is a pleiotropic cytokine which exerts a wide range of effects when administered in vivo . Using a murine model, we have investigated the effect of pretreatment with 1 µg (2.6 x 10 4 units) per mouse of recombinant murine TNF- on hematopoietic recovery following administration of cyclophosphamide, 5-fluorouracil, methotrexate, or vinblastine. TNF pretreatment results in enhanced regeneration of circulating neutrophils and hematopoietic progenitors, as measured by in vivo and in vitro assays, in animals given cycle-specific chemotherapeutic agents. The results may suggest that TNF affects cycle kinetics in hematopoietic progenitor cell populations, thus making these cells less prone to the cytocidal effects of the chemotherapeutic agents. As myeloablation is a frequent and often critical side effect following cancer treatment, these findings may have clinical implications. 1 This work was supported by USPHS Grants CA032516, CA-20194, and CA-23766 from the National Cancer Institute; American Cancer Society Grant CA-3K; and the Gar Reichman Fund of the Cancer Research Institute. D. J. W. is supported by a fellowship of the Leukemia Society of America. 2 Fellow of the Norwegian Cancer Society. To whom requests for reprints should be addressed, at the Clinical Pharmacology Unit, Department of Pharmacology and Toxicology, University of Bergen, N-5021 Bergen, Norway.

Journal

Cancer ResearchAmerican Association of Cancer Research

Published: Jul 15, 1990

There are no references for this article.